BNP Paribas Financial Markets Takes $532,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

BNP Paribas Financial Markets acquired a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 95,424 shares of the company's stock, valued at approximately $532,000. BNP Paribas Financial Markets owned approximately 0.21% of 4D Molecular Therapeutics at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. KLP Kapitalforvaltning AS acquired a new stake in shares of 4D Molecular Therapeutics in the fourth quarter worth $48,000. PNC Financial Services Group Inc. boosted its holdings in 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock worth $51,000 after buying an additional 3,630 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock valued at $55,000 after purchasing an additional 9,737 shares in the last quarter. Virtus ETF Advisers LLC boosted its position in 4D Molecular Therapeutics by 173.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company's stock worth $58,000 after acquiring an additional 6,560 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of 4D Molecular Therapeutics in the fourth quarter valued at approximately $69,000. Hedge funds and other institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Trading Up 5.2%

FDMT traded up $0.18 during midday trading on Thursday, hitting $3.65. The company's stock had a trading volume of 74,454 shares, compared to its average volume of 830,501. The firm has a market cap of $169.04 million, a P/E ratio of -1.28 and a beta of 2.87. 4D Molecular Therapeutics, Inc. has a 52-week low of $2.24 and a 52-week high of $28.93. The firm has a 50-day moving average price of $3.23 and a two-hundred day moving average price of $4.86.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). On average, equities analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on FDMT. Royal Bank of Canada dropped their price target on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. Bank of America dropped their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Weiss Ratings restated a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research note on Saturday, May 24th. Barclays decreased their target price on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Finally, The Goldman Sachs Group decreased their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, 4D Molecular Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $29.56.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.